Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Expanded use of Visudyne approved in E.U.

March 27, 2001

Iomed and Santen to develop treatment of posterior eye diseases

March 26, 2001

Two new antiglaucoma drugs approved by FDA

March 19, 2001

Six-month trial results show Lumigan clinically superior to timolol in lowering IOP

March 6, 2001

Japanese patent issued to Santen for new agents for glaucoma

March 1, 2001

Statistically significant phase II results reported for INS-365 Ophthalmic

Feb. 28, 2001

Santen granted rights to develop and market lomerizine for ophthalmological indications

Feb. 27, 2001

Promising data reported for Visudyne in occult AMD and pathological myopia

Feb. 14, 2001

GenVec to apply PEDF technology to the treatment of blindness

Feb. 13, 2001

FDA issues approvable letter for Visudyne

Feb. 5, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...